COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
29/05/2026
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Cannabix Expands BreathLogix Alcohol Screening Technology into Mining, Municipal and Aviation Sectors in Australia
29/05/2026
VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath devices is [...]
SRx Health Solutions Invests in Uber Technologies, Inc. and Provides Shareholders with Portfolio Update
29/05/2026
Reduced long position in Compass, Inc., reduced short exposure to Bitcoin and added selective hedges in select international markets EMJX stress model turned STRESS from MIXED this week – the first negative market [...]
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
29/05/2026
KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision [...]
The Next Great AI Revolution May Be Drug Delivery
29/05/2026
DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet [...]
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
29/05/2026
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
Sequana Medical Announces Presentation on Recompensation of Decompensated Cirrhosis Following alfapump® Placement at EASL Congress 2026
29/05/2026
Ghent, Belgium, May 29, 2026 (GLOBE NEWSWIRE) -- Post-hoc analysis from the POSEIDON study demonstrates long-term resolution of ascites and early signs of liver function recovery in over 20% of patients with alfapump in [...]
Gumitide Gummies Under Investigation: Examining Customer Complaints, Ingredients Claims and Serious Side Effects Risk
29/05/2026
Gumitide Gummies Scam or Legit: Apple Cider Vinegar and BHB Keto Weight Management Formula, Ingredients, Results, and Refund Terms Explained Largo, FL, May 28, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
Sequana Medical announces results of Annual General Meeting of Shareholders
28/05/2026
Ghent, Belgium, May 28, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE | REGULATED INFORMATION | 28 May 2026, 9:00 pm CEST Ghent, Belgium – 28 May 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " [...]
OSE Immunotherapeutics met en place un financement relais flexible en fonds propres
28/05/2026
Première étape d’une stratégie globale de financement ; la Société a intensifié ses interactions avec les investisseurs institutionnels aux Etats-Unis et en Europe Le produit brut pourrait représenter 19,3 millions d’ [...]
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
28/05/2026
First step of a global financing strategy, as the Company is actively engaging with institutional investors in the United States and in Europe Gross proceeds could amount to €19.3 million based on current share price 1 [...]
Parexel to Present Real-World Oncology Research and Launch New Patient-Focused Campaign at ASCO 2026
28/05/2026
Two virtual posters accepted exploring rejections in oncology marketing applications and real-world pulmonary safety of T-DXd in HER2-positive metastatic breast cancer From Insights to Life campaign reinforces Parexel’s [...]
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
28/05/2026
Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the [...]
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
28/05/2026
ISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab [...]
Apogee Therapeutics to Participate in Upcoming June Conferences
28/05/2026
SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences. Jefferies Global [...]
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
28/05/2026
GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for [...]
HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance
28/05/2026
Increases Repurchase Program by $1.0 Billion Highlights of the first quarter include: Net income increased 29% to $69.4 million , and net income margin increased to 20% from 16% last year. Adjusted EBITDA increased 17% [...]
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/05/2026
RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients [...]
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
28/05/2026
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it [...]

Pages